Troy Ignelzi
2021 - Karuna Therapeutics
In 2021, Troy Ignelzi earned a total compensation of $4.5M as Chief Financial Officer at Karuna Therapeutics, a 20% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $266,600 |
|---|---|
| Option Awards | $3,808,217 |
| Salary | $430,000 |
| Other | $8,700 |
| Total | $4,513,517 |
Ignelzi received $3.8M in option awards, accounting for 84% of the total pay in 2021.
Ignelzi also received $266.6K in non-equity incentive plan, $430K in salary and $8.7K in other compensation.
Rankings
In 2021, Troy Ignelzi's compensation ranked 2,938th out of 12,415 executives tracked by ExecPay. In other words, Ignelzi earned more than 76.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,938 out of 12,415 | 76th |
Division Manufacturing | 1,173 out of 5,508 | 79th |
Major group Chemicals And Allied Products | 468 out of 2,378 | 80th |
Industry group Drugs | 411 out of 2,099 | 80th |
Industry Pharmaceutical Preparations | 277 out of 1,549 | 82nd |
Source: SEC filing on April 27, 2022.
Ignelzi's colleagues
We found four more compensation records of executives who worked with Troy Ignelzi at Karuna Therapeutics in 2021.
News
Karuna Therapeutics CEO Steven Paul's 2021 pay jumps 48% to $13M
April 27, 2022
Karuna Therapeutics CEO Steven Paul's 2020 pay slips 11% to $8.9M
April 27, 2021
Karuna Therapeutics CEO Steven Paul's 2019 pay jumps 932% to $10M
April 29, 2020
scPharmaceuticals CEO John Tucker's 2019 pay slips 17% to $1.2M
April 27, 2020
scPharmaceuticals CEO John Tucker's 2018 pay falls 25% to $1.5M
April 30, 2019